Branded probiotic strain ibSium may support symptoms of IBS, says recent study

February 7, 2020

A clinical study recently published in the Journal of Colorectal Disease1 found that the proprietary probiotic strain Saccharomyces cerevisiae CNCM I-3856 (ibSium from Gnosis by Lesaffre) improved abdominal pain and bowel habits in subjects with irritable bowel syndrome (IBS). In the study, 100 volunteers with IBS (all subtypes included: IBS-C, IBS-D, IBS-M) were randomized to receive either the probiotic (2 capsules of 2.109 CFU per day) or placebo in addition to standard treatment (including antidiarrheal, laxative, antispasmodic) for the first 2 weeks and then taken alone for 6 weeks.

Results showed that in subjects taking the probiotic, abdominal pain score were reduced by 21% after four weeks and 26% after eight weeks. There were also significant improvements in stool consistency compared to placebo after four and eight weeks in the IBS-C and IBS-D populations. Over the second month of supplementation with the probiotic, stool consistency was classified as normal.

“Only few treatment options are both efficient and well-tolerated and only 8% of the people affected are satisfied with their current treatment,” said Elodie Ruffin, probiotics product manager of the Gnosis by Lesaffre company, in a press release. “Probiotics are already well-known by end-consumers to support digestive health. Considering these last findings, ibSium (S.cerevisiae CNCM I-3856) is definitely one of the most documented probiotic to support complete intestinal comfort and represents an alternative of natural origin for people suffering from gastrointestinal symptoms.”

The study’s results will be presented during the coming Probiota event in Dublin, from February 10 to 12.
 

References: 

1. Gayathri, et al. “Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome.” International Journal of Colorectal Disease, vol. 35, no 1 (2020): 139-145.